Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

ASAQ (Malaria)

ASAQ to treat malaria

= Fixed dose combination of Artesunate + Amodiaquine

  • Launched in 2007

  • The concrete results of an innovative partnership between DNDi and Sanofi

  • Meets the latest WHO guidelines for malaria treatment in Africa

  • Simple regimen: 1 or 2 tablets once a day for 3 days

  • Available at only 0.5$ for children, 1$ for adults

  • Meets the highest standard of quality

  • Made in the South for use in the South: ASAQ is produced in Marocco

  • Available under the name Artesunate-Amodiaquine Winthrop (ASAQ) for public market and Coarsucam for private market

Download ASAQ Press pack, March 1st 2007 [PDF 890KB]
Download ASAQ Newsletter, November 2009 [PDF 980KB]
Read more about ASAQ project
  ASAQ News
Implementation progress
More than 320 million treatments distributed

ASAQ registered in 35 countries & territories

Technology transfer to African industry partner ongoing
Recent Scientific Publications
Malaria Journal, December 2014
Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine
Malaria Journal, March 2014

Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009
Malaria Journal, July 2013
Efficacy of ASAQ and AL fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial 
Malaria Journal, July 2013
Tolerability and safety of ASAQ and AL fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License